Technical Analysis for ATOS - Atossa Genetics Inc.

Grade Last Price % Change Price Change
F 1.20 -6.25% -0.08
ATOS closed down 6.25 percent on Wednesday, November 20, 2024, on 2.26 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Stochastic Buy Signal Bullish 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Below Lower BB Weakness 0.00%
Gapped Down Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Calm After Storm Range Contraction -6.25%
NR7 Range Contraction -6.25%
Inside Day Range Contraction -6.25%
Oversold Stochastic Weakness -6.25%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 16 hours ago
Down 1 ATR about 21 hours ago
2x Volume Pace about 22 hours ago
1.5x Volume Pace about 22 hours ago
3x Volume Pace about 22 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Atossa Genetics Inc. Description

Atossa Genetics, Inc. operates as a healthcare company that focuses on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer in the United States. Its diagnostic tests include the ForeCYTE Breast Health Test, which provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65; and the ArgusCYTE Breast Health Test that offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company also intends to offers FullCYTE Breast Health Test, which is in development to assess the individual breast ducts for pre-cancerous changes in women; and NextCYTE Breast Cancer Test that is in the prevalidation phase to profile breast cancer specimens for prediction of treatment outcomes and distant recurrence in women newly diagnosed with breast cancer. Atossa Genetics, Inc. was founded in 2009 and is headquartered in Seattle, Washington.


Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Cancer Cancer Treatment Breast Cancer Genetics Diagnostic Tests Risk Assessment Assessment Products Breast Surgery Breast Implant Hereditary Cancers

Is ATOS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.31
52 Week Low 0.7
Average Volume 588,326
200-Day Moving Average 1.38
50-Day Moving Average 1.43
20-Day Moving Average 1.41
10-Day Moving Average 1.39
Average True Range 0.08
RSI (14) 32.43
ADX 14.87
+DI 16.38
-DI 29.01
Chandelier Exit (Long, 3 ATRs) 1.42
Chandelier Exit (Short, 3 ATRs) 1.43
Upper Bollinger Bands 1.59
Lower Bollinger Band 1.22
Percent B (%b) -0.05
BandWidth 26.55
MACD Line -0.04
MACD Signal Line -0.01
MACD Histogram -0.0283
Fundamentals Value
Market Cap 150.36 Million
Num Shares 125 Million
EPS -0.24
Price-to-Earnings (P/E) Ratio -5.00
Price-to-Sales 0.00
Price-to-Book 1.19
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.31
Resistance 3 (R3) 1.31 1.29 1.29
Resistance 2 (R2) 1.29 1.26 1.28 1.28
Resistance 1 (R1) 1.24 1.24 1.23 1.24 1.28
Pivot Point 1.22 1.22 1.21 1.21 1.22
Support 1 (S1) 1.17 1.19 1.16 1.17 1.12
Support 2 (S2) 1.15 1.17 1.14 1.12
Support 3 (S3) 1.10 1.15 1.11
Support 4 (S4) 1.10